Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease DrugInvestors Business Daily • 06/04/24
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)PRNewsWire • 06/04/24
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.The Motley Fool • 06/03/24
Here's Why Viking Therapeutics, Inc. (VKTX) Gained But Lagged the Market TodayZacks Investment Research • 05/31/24
If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 NamesInvestorPlace • 05/29/24
If You'd Invested $100 in Viking Therapeutics Stock 2 Years Ago, Here's How Much You'd Have TodayThe Motley Fool • 05/26/24
Wall Street Favorites: 3 Russell 2000 Stocks With Strong Buy Ratings for May 2024InvestorPlace • 05/20/24
What Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma PartnerSeeking Alpha • 05/12/24